Genetic and immunologic studies of patients on procainamide

Area of Science:

• Immunogenetics
• Pharmacogenetics
• Cardiology

Background:

• Cardiac arrhythmias necessitate drug therapies like procainamide (PA).
• Genetic factors can influence drug efficacy and adverse reactions.
• Human Leukocyte Antigen (HLA) and complement system variations are implicated in immune responses.

Purpose of the Study:

• To investigate associations between HLA class II, DQB1*03 subtypes, and complement C4 allotypes in patients receiving PA.
• To evaluate the role of acetylation phenotype and cytokine production (IL-1 beta, TNF alpha) in PA-treated patients.
• To identify potential genetic markers influencing host responsiveness to PA therapy.

Main Methods:

• Analysis of HLA class II phenotypes (DRB1*04, DQB1*03) in 40 PA patients and 24 controls.
• Assessment of complement C4 null alleles and acetylation phenotype in PA patients.
• Measurement of Interleukin-1 beta and Tumor Necrosis Factor alpha secretion by stimulated cells and peripheral blood leukocytes.

Main Results:

• No association found between acetylation phenotype and HLA class II or C4 allotypes.
• Significant increase in class III C4 complement allotypes in PA patients compared to controls.
• Significant increase in autoantibodies and DQw3 phenotypes observed in the PA patient group.
• Spontaneous IL-1 and TNF production suggested a possible link between certain HLA class II phenotypes and PA response.

Conclusions:

• Class III C4 complement allotypes and DQw3 phenotypes are more prevalent in patients on procainamide therapy.
• Genetic variations, particularly in HLA class II, may play a role in individual responses to PA.
• Further research is warranted to elucidate the immunogenetic mechanisms underlying PA treatment outcomes.